Nils Brünner

Professor University of Copenhagen
Co-founder of Scandion Oncology A/S

Carit Andersen
Chief Financial Officer

Associate Professor
University of Southern DK

Jan Stenvang, Co-founder
Chief Scientific Officer

MSc, PhD
Associate Professor, University of Copenhagen

Peter Michael Vestlev, MD, CBA, MPP

Chief Physician, Oncologist, Region Sjælland
Previously, consultant for the Danish Medicines Agency



Scandion Oncology has two promising compounds in the pipeline, including SCO-101, which has completed four Phase I trials, and SCO-201, which is in preclinical testing stages. We aim to conclude one Phase II trial within the next 2 years. Upon conclusion of the Phase II trial, we will be ready to consider exit or partner options.

Clinical Trials

Our lead compound – SCO-101 – has been shown to enhance the effect of certain standard chemotherapy when given in combination. We are planning one Phase II trial within metastatic breast cancer. We are simultaneously developing SCO-201, which will target other solid tumors.


Detailed analyses suggests the market for Scandion Oncology’s products to be more than EUR 4 billion annually. We believe our patents could be attractive for larger pharmaceutical companies to combine with their existing cancer treatments.